Full Press Release Details
Health to Host Investor Call April 6th at 8:30 a.m. Eastern Regarding Q4 2019 Financials & Business Updates
Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019
Francisco, CA (April 3, 2020): Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar"
or the "Company") today announced that Company management will host a conference call on Monday, April 6, 2020 at
8:30 a.m. Eastern Time to provide updates regarding fourth-quarter 2019 financials and business updates.
On April 3, 2020 the
Company filed with the U.S. Securities and Exchange Commission its annual report on Form 10-K for the fiscal year ended
Instructions for Conference Call
6, 2020 at 8:30 a.m. Eastern Time
Toll Free): 888-394-8218
Dial-in (International):
webcast on the investor relations section of Jaguar's website (click here)
Toll Free): 844-512-2921
Dial-in (International):
of the webcast on the investor relations section of Jaguar's website (click here)
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial
stage pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our
wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal
pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi (crofelemer)
product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral
more information about Jaguar, please visit jaguar.health. For more information about Napo,
visit napopharma.com.
is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral
therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies
of diarrhea before starting Mytesi . If infectious etiologies are not considered, there is a risk that patients
with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most
common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%),
cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
information and complete Prescribing Information are available at Mytesi.com. Crofelemer,
the active ingredient in Mytesi , is a botanical (plant-based) drug extracted and purified from the red bark sap
of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for
crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press
release constitute "forward-looking statements." These include statements regarding the expectation that Jaguar will
host a conference call on April 6, 2020. In some cases, you can identify forward-looking statements
by terms such as "may," "will," "should," "expect," "plan," "aim,"
"anticipate," "could," "intend," "target," "project," "contemplate,"
"believe," "estimate," "predict," "potential" or "continue" or the
negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar
has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking
statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable
law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of
any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.